| Encorafenib studied in …STUDIED_INderived68 of 68show fewer |
|---|
| → studied in | NCT06102902Phase 1 · recruiting Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer · 68 trials list this drug (28 active) | — | — | Colorectal Adenocarcinoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04511013Phase 2 · recruiting A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases · 68 trials list this drug (28 active) | — | — | Melanoma,Cutaneous Melanoma,Mucosal Melanoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05985954Phase 1 · recruiting Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy · 68 trials list this drug (28 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06578559Phase 2 · active not recruiting Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC · 68 trials list this drug (28 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04657991Phase 3 · active not recruiting A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma · 68 trials list this drug (28 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04526782Phase 2 · active not recruiting ENCOrafenib With Binimetinib in bRAF NSCLC · 68 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04221438Phase 2 · terminated Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement · 68 trials list this drug (28 active) | — | — | Cutaneous Melanoma,Melanoma of Unknown Primary | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05217446Phase 2 · active not recruiting A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer · 68 trials list this drug (28 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03693170Phase 2 · completed Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer · 68 trials list this drug (28 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05308446Phase 2 · active not recruiting Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation · 68 trials list this drug (28 active) | — | — | Colon Adenocarcinoma,Malignant Colon Neoplasm,Malignant Rectal Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05710406Phase 2/Phase 3 · active not recruiting Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer · 68 trials list this drug (28 active) | — | — | Colon Adenocarcinoma,Malignant Colon Neoplasm,Microsatellite Stable Colon Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04324112Phase 2 · active not recruiting Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL · 68 trials list this drug (28 active) | — | — | Hairy Cell Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02910700Phase 2 · active not recruiting Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma · 68 trials list this drug (28 active) | — | — | Melanoma,Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04017650Phase 1/Phase 2 · active not recruiting Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer · 68 trials list this drug (28 active) | — | — | Colorectal Carcinoma,Malignant Colorectal Neoplasm,Colon Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04607421Phase 3 · active not recruiting A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer · 68 trials list this drug (28 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07318389early Phase 1 · not yet recruiting ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer · 68 trials list this drug (28 active) | — | — | Colorectal Neoplasm,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03839342Phase 2 · active not recruiting Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations · 68 trials list this drug (28 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04074096Phase 2 · active not recruiting Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis · 68 trials list this drug (28 active) | — | — | Melanoma,Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04800822Phase 1 · terminated PF-07284892 in Participants With Advanced Solid Tumors · 68 trials list this drug (28 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05615818Phase 3 · recruiting Personalized Medicine for Advanced Biliary Cancer Patients · 68 trials list this drug (28 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05195632Phase 2 · active not recruiting Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer · 68 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05004350Phase 2 · completed A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. · 68 trials list this drug (28 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05026983Phase 2 · recruiting Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases · 68 trials list this drug (28 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04061980Phase 2 · active not recruiting Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer · 68 trials list this drug (28 active) | — | — | Differentiated Thyroid Gland Carcinoma,Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05039177Phase 1/Phase 2 · completed A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies · 68 trials list this drug (28 active) | — | — | Malignant Colorectal Neoplasm,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03915951Phase 2 · completed An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer · 68 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05926960Phase 2 · terminated A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma · 68 trials list this drug (28 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01909453Phase 3 · completed Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma · 68 trials list this drug (28 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04903119Phase 1 · recruiting Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma · 68 trials list this drug (28 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03543969early Phase 1 · active not recruiting Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma · 68 trials list this drug (28 active) | — | — | Malignant Skin Neoplasm,Melanoma,Cutaneous Melanoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04585815Phase 1/Phase 2 · terminated Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) · 68 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06194929Phase 1/Phase 2 · recruiting Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma · 68 trials list this drug (28 active) | — | — | Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05743036Phase 1 · terminated ZN-c3 in Adult Participants With Metastatic Colorectal Cancer · 68 trials list this drug (28 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05304546Phase 2 · completed Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma · 68 trials list this drug (28 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03898908Phase 2 · completed Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain · 68 trials list this drug (28 active) | — | — | Melanoma,Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05260684completed Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US · 68 trials list this drug (28 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06411600Phase 2 · recruiting Combination Therapy for BRAF-V600E Metastatic CRCm · 68 trials list this drug (28 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03973918Phase 2 · terminated Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG · 68 trials list this drug (28 active) | — | — | Anaplastic Astrocytoma,Anaplastic Pleomorphic Xanthoastrocytoma,Glioblastoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01436656Phase 1 · completed A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma · 68 trials list this drug (28 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03843775Phase 1/Phase 2 · completed A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers · 68 trials list this drug (28 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03864042Phase 1 · completed Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors · 68 trials list this drug (28 active) | — | — | Solid Neoplasm,Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01894672Phase 2 · completed BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation · 68 trials list this drug (28 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05003622Phase 1 · completed Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors · 68 trials list this drug (28 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02631447Phase 2 · completed Sequential Combo Immuno and Target Therapy (SECOMBIT) Study · 68 trials list this drug (28 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04655157Phase 1/Phase 2 · terminated Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma · 68 trials list this drug (28 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04390243Phase 2 · terminated Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation · 68 trials list this drug (28 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01543698Phase 1/Phase 2 · completed A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors · 68 trials list this drug (28 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02159066Phase 2 · completed LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma · 68 trials list this drug (28 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04720768Phase 1/Phase 2 · unknown Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE · 68 trials list this drug (28 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02928224Phase 3 · completed Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer · 68 trials list this drug (28 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02834364Phase 2 · completed BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) · 68 trials list this drug (28 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03563729Phase 2 · recruiting Melanoma Metastasized to the Brain and Steroids · 68 trials list this drug (28 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03911869Phase 2 · terminated An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis · 68 trials list this drug (28 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04801966NA · terminated Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study · 68 trials list this drug (28 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03878719Phase 1 · terminated Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma · 68 trials list this drug (28 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05725200Phase 2 · recruiting Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer · 68 trials list this drug (28 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04044430Phase 1 · terminated Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer · 68 trials list this drug (28 active) | — | — | Colorectal Adenocarcinoma,Malignant Colorectal Neoplasm,Colon Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02857270Phase 1 · completed A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer · 68 trials list this drug (28 active) | — | — | Malignant Neoplasm,Melanoma,Lung Non-Small Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04673955recruiting BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment · 68 trials list this drug (28 active) | — | — | Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02675946Phase 1 · unknown CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) · 68 trials list this drug (28 active) | — | — | Digestive System Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01719380Phase 2 · completed Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer · 68 trials list this drug (28 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01981187Phase 2 · terminated LGX818 for Patients With BRAFV600 Mutated Tumors · 68 trials list this drug (28 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02902042Phase 1/Phase 2 · completed Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma · 68 trials list this drug (28 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04045691recruiting Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment · 68 trials list this drug (28 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02109653Phase 2 · withdrawn Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC · 68 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02278133Phase 1/Phase 2 · completed Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations · 68 trials list this drug (28 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01820364Phase 2 · terminated LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma · 68 trials list this drug (28 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01777776Phase 1/Phase 2 · terminated Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. · 68 trials list this drug (28 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |